Results 91 to 100 of about 67,119 (304)

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, EarlyView.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab

Journal of Blood Medicine, 2021
Marilyn T Nedumcheril,1,2 Robert A DeSimone,1 Sabrina E Racine-Brzostek,1 Ok Kyong Chaekal,1,3 Ljiljana V Vasovic1 1Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA; 2New York ...
Nedumcheril MT, DeSimone RA, Racine-Brzostek SE, Chaekal OK, Vasovic LV   +4 more
doaj  

CD38 as theranostic target in oncology

Journal of Translational Medicine
CD38 is a multifunctional transmembrane glycoprotein found in multiple tissues and overexpressed in many cancer cells, notably in hematological malignancies such as leukemia and multiple myeloma (MM). Therefore, targeting CD38 remains an attractive strategy for cancer treatment in hematological malignancies as well as in solid tumors.
Bocuzzi, Valentina, Bridoux, Jessica, PIROTTE, Michelle, Withofs, Nadia, Hustinx, Roland, D'Huyvetter, Matthias, Caers, Jo, Marcion, Guillaume   +7 more
openaire   +4 more sources

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38 [PDF]

BackgroundCD38 and CD47 are expressed in many hematologic malignancies, including multiple myeloma (MM), B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), and B-cell chronic lymphocytic leukemia (CLL).
Chunmei Yang, Nana Sun, Wei Zhang, Xiaoping Tu, Song Li, Guanghui Li, Gui Zhao, Li Zhang, Wenzhi Tian, Huiqin Guo, Xing Bai, Ruliang Zhang, Dianze Chen, Kaili Wang, Tengfei Li, Yanan Yang, Liang Peng, Sijin Liu, Dandan Liu   +18 more
core   +1 more source

Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma

Clinical Pharmacology &Therapeutics, EarlyView.
The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed ...
Thomas E. Kraft, Estelle Marrer‐Berger, Sara Belli, Helene Haegel, Anneliese Schneider, Anna Maria Giusti, Michael Bscheider, Wolfgang Jacob, Martin Weisser, Laura Blanco, Nicolas Frances, Eva Rossmann, Guido Steiner, Aintzane Zabaleta Azpiroz, Bruno Paiva, Ludovic Martinet, Tanja Fauti   +16 more
wiley   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

ANALYSIS OF T-HELPER SUBSETS OF PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC HEPATITIS C EXPRESSING CHEMOKINE RECEPTORS CXCR3 AND CCR6 AND ACTIVATION MARKERS CD38 AND HLA-DR

Инфекция и иммунитет, 2014
. In case of hepatitis C the adequate adaptive immune response depends on T-helper lymphocyte subsets and recruiting specific T cells in the site of infection.
D. S. Elezov, I. V. Kudryavtsev, N. A. Arsentieva, A. V. Semenov, E. V. Esaulenko, V. V. Basina, Areg A. Totolian   +6 more
doaj   +1 more source

CD38 connects the heart and brain

Translational Psychiatry
Cluster of differentiation 38 (CD38) is a widely expressed transmembrane glycoprotein in various human tissues and cells with vital biological roles in the heart and brain, possessing both NADase and cyclase activities. It is involved in regulating heart and brain functions through various pathways, including calcium (Ca2+) signaling nicotinamide ...
Yijing Tao, Jiahao Duan, Kai Huang, Ruting Wang, Qinwen Feng, Chun Yang, Xinying Zhang, Ling Yang   +7 more
openaire   +3 more sources

Establishment of pediatric reference ranges for circulating naïve and memory T and B cell subsets guided by the human immunophenotyping consortium standardization initiative: A large, single center U.S. experience

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice ...
Aaruni Khanolkar, Aisha Ahmed
wiley   +1 more source

Evidence for targeting of CD38 mRNA by the post-transcriptional regulator protein ZFP36L1

, 2015
Introduction: The ZFP36 family of post-transcriptional regulator proteins include ZFP36, ZFP36L1 and ZFP36L2. These proteins are post-transcriptional regulators of gene expression that bind to adenine uridine rich elements (AREs) in the 3’ untranslated ...
Murphy, J.J.
core